UNIQURE NV (QURE) Fundamental Analysis & Valuation
NASDAQ:QURE • NL0010696654
Current stock price
15.38 USD
-0.92 (-5.64%)
At close:
15.5 USD
+0.12 (+0.78%)
After Hours:
This QURE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. QURE Profitability Analysis
1.1 Basic Checks
- QURE had negative earnings in the past year.
- QURE had a negative operating cash flow in the past year.
- QURE had negative earnings in 4 of the past 5 years.
- In the past 5 years QURE reported 4 times negative operating cash flow.
1.2 Ratios
- QURE's Return On Assets of -24.12% is fine compared to the rest of the industry. QURE outperforms 72.15% of its industry peers.
- QURE has a Return On Equity of -100.04%. This is comparable to the rest of the industry: QURE outperforms 43.52% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.12% | ||
| ROE | -100.04% | ||
| ROIC | N/A |
ROA(3y)-34.75%
ROA(5y)-16.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- QURE's Gross Margin of 89.53% is amongst the best of the industry. QURE outperforms 91.30% of its industry peers.
- QURE's Gross Margin has declined in the last couple of years.
- The Profit Margin and Operating Margin are not available for QURE so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.53% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.57%
GM growth 5YN/A
2. QURE Health Analysis
2.1 Basic Checks
- QURE does not have a ROIC to compare to the WACC, probably because it is not profitable.
- The number of shares outstanding for QURE has been increased compared to 1 year ago.
- QURE has more shares outstanding than it did 5 years ago.
- Compared to 1 year ago, QURE has an improved debt to assets ratio.
2.2 Solvency
- QURE has an Altman-Z score of -1.14. This is a bad value and indicates that QURE is not financially healthy and even has some risk of bankruptcy.
- QURE's Altman-Z score of -1.14 is in line compared to the rest of the industry. QURE outperforms 53.00% of its industry peers.
- A Debt/Equity ratio of 2.63 is on the high side and indicates that QURE has dependencies on debt financing.
- QURE has a Debt to Equity ratio of 2.63. This is in the lower half of the industry: QURE underperforms 79.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.63 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.14 |
ROIC/WACCN/A
WACC6.23%
2.3 Liquidity
- A Current Ratio of 10.43 indicates that QURE has no problem at all paying its short term obligations.
- Looking at the Current ratio, with a value of 10.43, QURE belongs to the top of the industry, outperforming 80.66% of the companies in the same industry.
- A Quick Ratio of 10.43 indicates that QURE has no problem at all paying its short term obligations.
- With an excellent Quick ratio value of 10.43, QURE belongs to the best of the industry, outperforming 80.66% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 10.43 | ||
| Quick Ratio | 10.43 |
3. QURE Growth Analysis
3.1 Past
- QURE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 28.69%, which is quite impressive.
- The Revenue for QURE has decreased by -40.64% in the past year. This is quite bad
- QURE shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -15.56% yearly.
EPS 1Y (TTM)28.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.89%
Revenue 1Y (TTM)-40.64%
Revenue growth 3Y-46.73%
Revenue growth 5Y-15.56%
Sales Q2Q%6.65%
3.2 Future
- The Earnings Per Share is expected to grow by 29.94% on average over the next years. This is a very strong growth
- Based on estimates for the next years, QURE will show a very strong growth in Revenue. The Revenue will grow by 122.75% on average per year.
EPS Next Y2.09%
EPS Next 2Y17.58%
EPS Next 3Y29.9%
EPS Next 5Y29.94%
Revenue Next Year132.48%
Revenue Next 2Y164.28%
Revenue Next 3Y103.8%
Revenue Next 5Y122.75%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. QURE Valuation Analysis
4.1 Price/Earnings Ratio
- QURE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for QURE. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- QURE's earnings are expected to grow with 29.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.58%
EPS Next 3Y29.9%
5. QURE Dividend Analysis
5.1 Amount
- QURE does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
QURE Fundamentals: All Metrics, Ratios and Statistics
15.38
-0.92 (-5.64%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-02 2026-03-02/bmo
Earnings (Next)N/A N/A
Inst Owners99.92%
Inst Owner Change0%
Ins Owners1.44%
Ins Owner Change1.12%
Market Cap961.71M
Revenue(TTM)16.10M
Net Income(TTM)-198.97M
Analysts80.95
Price Target37.83 (145.97%)
Short Float %21.82%
Short Ratio3.49
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.35%
Min EPS beat(2)-50.39%
Max EPS beat(2)33.69%
EPS beat(4)3
Avg EPS beat(4)6.92%
Min EPS beat(4)-50.39%
Max EPS beat(4)33.69%
EPS beat(8)5
Avg EPS beat(8)-11.92%
EPS beat(12)5
Avg EPS beat(12)-37.76%
EPS beat(16)8
Avg EPS beat(16)-19.46%
Revenue beat(2)1
Avg Revenue beat(2)-12.95%
Min Revenue beat(2)-30.8%
Max Revenue beat(2)4.9%
Revenue beat(4)1
Avg Revenue beat(4)-27.84%
Min Revenue beat(4)-75.51%
Max Revenue beat(4)4.9%
Revenue beat(8)3
Avg Revenue beat(8)-19.73%
Revenue beat(12)4
Avg Revenue beat(12)-34.69%
Revenue beat(16)5
Avg Revenue beat(16)-19.09%
PT rev (1m)-26.57%
PT rev (3m)-30.27%
EPS NQ rev (1m)7.04%
EPS NQ rev (3m)5.89%
EPS NY rev (1m)0%
EPS NY rev (3m)-5.27%
Revenue NQ rev (1m)-1.61%
Revenue NQ rev (3m)-5.48%
Revenue NY rev (1m)-0.01%
Revenue NY rev (3m)-14.03%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 59.74 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 4.84 | ||
| P/tB | 9.54 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.53
EYN/A
EPS(NY)-3.46
Fwd EYN/A
FCF(TTM)-2.85
FCFYN/A
OCF(TTM)-2.85
OCFYN/A
SpS0.26
BVpS3.18
TBVpS1.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.12% | ||
| ROE | -100.04% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 89.53% | ||
| FCFM | N/A |
ROA(3y)-34.75%
ROA(5y)-16.3%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.57%
GM growth 5YN/A
F-Score5
Asset Turnover0.02
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 2.63 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 2.97% | ||
| Cap/Sales | 2.73% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 10.43 | ||
| Quick Ratio | 10.43 | ||
| Altman-Z | -1.14 |
F-Score5
WACC6.23%
ROIC/WACCN/A
Cap/Depr(3y)29.91%
Cap/Depr(5y)107.27%
Cap/Sales(3y)20.1%
Cap/Sales(5y)16.05%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)28.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%57.89%
EPS Next Y2.09%
EPS Next 2Y17.58%
EPS Next 3Y29.9%
EPS Next 5Y29.94%
Revenue 1Y (TTM)-40.64%
Revenue growth 3Y-46.73%
Revenue growth 5Y-15.56%
Sales Q2Q%6.65%
Revenue Next Year132.48%
Revenue Next 2Y164.28%
Revenue Next 3Y103.8%
Revenue Next 5Y122.75%
EBIT growth 1Y-4.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year20.09%
EBIT Next 3Y9.41%
EBIT Next 5Y37.04%
FCF growth 1Y4.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.61%
OCF growth 3YN/A
OCF growth 5YN/A
UNIQURE NV / QURE Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for UNIQURE NV?
ChartMill assigns a fundamental rating of 3 / 10 to QURE.
What is the valuation status for QURE stock?
ChartMill assigns a valuation rating of 1 / 10 to UNIQURE NV (QURE). This can be considered as Overvalued.
Can you provide the profitability details for UNIQURE NV?
UNIQURE NV (QURE) has a profitability rating of 2 / 10.
Can you provide the expected EPS growth for QURE stock?
The Earnings per Share (EPS) of UNIQURE NV (QURE) is expected to grow by 2.09% in the next year.